BioPharma Dive tapped into the expertise of top thought leaders in the industry to get their takes on what comes next in pricing, M&As, drug development, transparency and much more. "Bain has demonstrated how biopharma leaders have created the most shareholder value by focusing on a few, sustainable leadership positions in Product Categories (distinct from Therapeutic Areas)," said Ashish Singh, the leader of Bain & Company's Global Healthcare practice. "This focused strategy of Category Leadership has been proven to provide superior returns on investment in R&D and commercial."